Effects of rhBNP in Pediatrics After Corrective Repair of Tetralogy Of Fallot

NACompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 1, 2013

Primary Completion Date

December 31, 2017

Study Completion Date

July 20, 2019

Conditions
Congenital Heart DefectsTetralogy Of Fallot
Interventions
DRUG

recombinant human brain natriuretic peptide (rhBNP)

Patients are first given a loading dose of recombinant human brain natriuretic peptide (rhBNP) 1.5 mcg/kg, followed by continuous infusion recombinant human brain natriuretic peptide 0.01-0.01mcg/kg/min for 72 hours.

DRUG

Placebo (0.9% sodium chloride)

Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a placebo infusion 24 hours after operation.

Trial Locations (1)

200127

Cardiac intensive care unit, Department of cardiothoracic vascular surgery, Shanghai Children's Medical Center, Medical college of Shanghai Jiaotong University, Shanghai

All Listed Sponsors
lead

Shanghai Jiao Tong University School of Medicine

OTHER

NCT01941576 - Effects of rhBNP in Pediatrics After Corrective Repair of Tetralogy Of Fallot | Biotech Hunter | Biotech Hunter